Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

Night blindness, or nyctalopia, is the inability to see well in low light conditions, often signalling an underlying issue with the eyes or other health problems.

THE loss of dark adaptation and night blindness which characterizes the earliest stages of retinitis pigmentosa suggested to us the possibility that one of the fundamental features of the ...

This important Research Advance presents convincing evidence on the neuroprotective effects of reserpine in a well-established model of retinitis pigmentosa (P23H-1 ... (A,B) Rod photoreceptors were ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 in the open-access ...

VP-001 is under clinical development by PYC Therapeutics and currently in Phase I for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase I drugs for Retinitis Pigmentosa (Retinitis) have ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...